The effect of dosing sequence of programmed death receptor-1 inhibitors combined with chemotherapy on adverse effects in the real world
The dosing sequence of PD-1 inhibitors combined with chemotherapy is closely related to the occurrence of adverse events. Administering PD-1 inhibitors first can reduce the risk of adverse events, and the choice of dosing sequence should be paid attention to in clinical practice.
Authors
- Ziyuan Zhou
- Yuelin Zhang (ORCID: https://orcid.org/0000-0002-0065-1116)
- Jun Meng (ORCID: https://orcid.org/0000-0002-8890-8915)
- Haïwen Tang
Institutions
- Guangdong Medical College (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Peking University Shenzhen Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-15
- DOI
- https://doi.org/10.3389/fonc.2025.1645091
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- Sanming Project of Medicine in Shenzhen